PepVault News · About
About PepVault News.
The peptide and GLP-1 stories the crowd follows, checked at the primary source, with the link to that source first.
Who publishes it
PepVault News is published by PepVault, the peptide resource at pepvault.app and the PepVault app for iPhone. Stories carry PepVault’s name.
What we cover
- GLP-1s and the incretin pipeline: semaglutide, tirzepatide, retatrutide, orforglipron, CagriSema and the drugs coming after them.
- Research peptides and the rules around them: compounding, FDA policy and the advisory meetings that shape it.
- New trial results and papers on the peptides people use, with the species or trial stage named.
- The big obesity and endocrine meetings, and the drugmakers’ results calls. The calendar lists what’s scheduled.
How we check a story
- Every claim is checked at its primary source: the company’s release, the regulator’s notice, the trial registry or the paper.
- That source is linked at the top of every story, with the time it first went public.
- A story marked BREAKING carries news that first went public within the last 72 hours. Older news is never posted as breaking.
- A lab or animal finding names its species. A story reports what happened; it isn’t medical advice.
Corrections
When we get something wrong, we correct it in the open, on the story’s own page, and its updated date moves with the fix.
A story that can’t stand is retracted, never deleted: it keeps its address with a banner that says why, so a link to it never breaks.
Contact
Tips, corrections and questions: hello@pepvault.app.